Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer (Q38370174)

2 September 2017

1 reference

title

Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer (English)

1 reference

2 September 2017

0 references

1 reference

Shinji Tanaka

1

1 reference

2 September 2017

publication date

7 March 2015

1 reference

Annals of Surgical Oncology

2 September 2017

published in

1 reference

2 September 2017

volume

23 Suppl 2

1 reference

2 September 2017

page(s)

S197-205

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

2 September 2017

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

EGF receptor is required for KRAS-induced pancreatic tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Stromal depletion goes on trial in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Current understanding of the molecular biology of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

From tissue turnover to the cell of origin for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4463-X

10.1245/S10434-015-4463-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1046007770

0 references

1 reference